Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02798419 · ClinicalTrials.gov registry record · Phase 2

Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

A Phase 2 study of Common Warts, sponsored by Dr. Reddys Laboratories.

Completed
Registry status
Phase 2
Development phase
50
Enrollment target
12
Study locations

NCT02798419 is a Phase 2 study of Common Warts that has completed, run by Dr. Reddys Laboratories. The registered enrollment target is 50 participants, below the 141-participant average among 3 other Common Warts trials with a reported enrollment target (65% lower). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02798419, a Phase 2 study of Common Warts, has completed, sponsored by Dr. Reddys Laboratories.

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target
12
Study locations

Study Summary

DFD05 vs. Active01 in the treatment of common warts

Conditions Studied

Interventions

  • DRUG DFD05 Cream
  • DRUG Active01 Cream

Study Locations (12)

California

  • Investigational Site #4 - Fremont
  • Investigational Site #11 - Sacramento

Texas

  • Investigational Site #5 - Austin
  • Investigational Site #7 - College Station

Arkansas

  • Investigation Site #1 - Hot Springs

Colorado

  • Investigational Site #2 - Colorado Springs

Florida

  • Investigational Site #12 - Tampa

Georgia

  • Investigational Site #9 - Marietta

Illinois

  • Investigational Site #3 - Arlington Hts

Louisiana

  • Investigational Site #10 - Crowley

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2016-01
Est. Completion 2016-08
Phase Phase 2

Sponsor

Dr. Reddys Laboratories

1 total trials

What the Registry Record Tells You About NCT02798419

The ClinicalTrials.gov registry entry for NCT02798419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 141-participant average among 3 other Common Warts trials with a reported enrollment target (65% lower). The listed sponsor is Dr. Reddys Laboratories, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Common Warts appearing as the primary indexed condition, and to 2 interventions - of which DFD05 Cream is the first listed.

NCT02798419 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Texas, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02798419 about?

NCT02798419 is a clinical study titled "Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts". DFD05 vs. Active01 in the treatment of common warts

What is the current status of trial NCT02798419?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-01. Estimated completion is 2016-08.

What conditions does trial NCT02798419 study?

This clinical trial studies the following conditions: Common Warts.

What interventions are being tested in trial NCT02798419?

The interventions under investigation include: DFD05 Cream (DRUG), Active01 Cream (DRUG).

Who is sponsoring clinical trial NCT02798419?

This trial is sponsored by Dr. Reddys Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02798419 being conducted?

This trial has 12 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Common Warts

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.